Takeda's Zasocitinib Phase 3 Psoriasis Data Shows Rapid, Durable Skin Clearance; NDA Submission Planned

summarizeSummary

Takeda announced detailed positive Phase 3 results for its oral TYK2 inhibitor, zasocitinib, in plaque psoriasis, demonstrating rapid and durable skin clearance with a favorable safety profile, and plans for regulatory submission in FY2026.

check_boxKey Events

• Positive Phase 3 Results for Zasocitinib

  Takeda reported detailed positive data from two pivotal Phase 3 studies (Latitude PsO 3001 and 3002) for zasocitinib (TAK-279) in moderate-to-severe plaque psoriasis.

• Strong Efficacy Profile

  Approximately 70% of patients achieved clear or almost clear skin (sPGA 0/1) at week 16. The drug demonstrated rapid response (PASI 75 as early as week 4) and durable skin clearance, with over 90% of patients maintaining response at week 60.

• Favorable Safety Profile

  Zasocitinib was generally well-tolerated, with a safety profile consistent with prior studies and no new safety signals identified through week 24.

• Regulatory Submission Planned

  The company is on track to submit a New Drug Application (NDA) with the US FDA and other regulatory authorities starting in fiscal year 2026.

auto_awesomeAnalysis

This filing provides comprehensive Phase 3 data for zasocitinib, a key pipeline asset, which was presented at the American Academy of Dermatology. The strong efficacy, including high rates of clear skin and durable responses, combined with a consistent safety profile, positions zasocitinib as a potential leading oral treatment for moderate-to-severe plaque psoriasis. The company's plan to submit an NDA in fiscal year 2026, along with an estimated global peak revenue potential of $3-6 billion for psoriasis and psoriatic arthritis, underscores the drug's significant commercial opportunity and its importance to Takeda's future growth trajectory. This positive development comes as the stock is trading near its 52-week high, reinforcing investor confidence in the company's pipeline.